BR112022002176A2 - Nanoemulsão de ácido 18ss-glicirretínico. - Google Patents

Nanoemulsão de ácido 18ss-glicirretínico.

Info

Publication number
BR112022002176A2
BR112022002176A2 BR112022002176A BR112022002176A BR112022002176A2 BR 112022002176 A2 BR112022002176 A2 BR 112022002176A2 BR 112022002176 A BR112022002176 A BR 112022002176A BR 112022002176 A BR112022002176 A BR 112022002176A BR 112022002176 A2 BR112022002176 A2 BR 112022002176A2
Authority
BR
Brazil
Prior art keywords
glycyrrhetinic acid
particle size
therapeutic uses
effect
pharmaceutical forms
Prior art date
Application number
BR112022002176A
Other languages
English (en)
Inventor
Zendejas Hernández Ulises
Original Assignee
Atso Corp Affairs S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atso Corp Affairs S A De C V filed Critical Atso Corp Affairs S A De C V
Publication of BR112022002176A2 publication Critical patent/BR112022002176A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

nanoemulsão de ácido 18ß-glicirretínico. a invenção refere-se a formas farmacêuticas que potencializam a biodisponibilidade do 18ß-ga, possuindo alta permeação na área de aplicação principalmente devido ao efeito de seu pequeno tamanho de partícula, alta concentração do princípio ativo, composição do excipiente, micelas com composição estrutural específica e polaridade. as presentes formas farmacêuticas apresentam valores específicos para tamanho de partícula, permeabilidade, coeficiente de difusão e polidispersidade ajudando a fornecer suas vantagens técnicas. também são descritos os usos terapêuticos das formas farmacêuticas, que incluem aqueles usos terapêuticos para os quais o ácido 18ß-glicirretínico é conhecido por ter um efeito, como atividade anti-inflamatória, antiviral, antibacteriana, hepatoprotetora, usada contra doenças de pele e anticarcinogênica. principalmente soluções gelificadas, emulsões e nanoemulsões, destinam-se à aplicação na área vaginal e cervical, para o tratamento de doenças relacionadas ao papilomavírus humano, como infecções, lesões e câncer do colo do útero.
BR112022002176A 2019-08-08 2020-08-07 Nanoemulsão de ácido 18ss-glicirretínico. BR112022002176A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2019009482A MX2019009482A (es) 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.
PCT/MX2020/050025 WO2021025550A1 (es) 2019-08-08 2020-08-07 Nanoemulsion de ácido 18p-glicirretínico

Publications (1)

Publication Number Publication Date
BR112022002176A2 true BR112022002176A2 (pt) 2022-05-03

Family

ID=74503526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002176A BR112022002176A2 (pt) 2019-08-08 2020-08-07 Nanoemulsão de ácido 18ss-glicirretínico.

Country Status (9)

Country Link
US (1) US20220296544A1 (pt)
EP (1) EP4023219A4 (pt)
CN (1) CN114450001A (pt)
BR (1) BR112022002176A2 (pt)
CA (1) CA3147206A1 (pt)
CO (1) CO2022002493A2 (pt)
MX (1) MX2019009482A (pt)
WO (1) WO2021025550A1 (pt)
ZA (1) ZA202202125B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159476A1 (en) 2022-02-25 2023-08-31 L'oreal Composition for caring for keratin materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2072014B (en) * 1980-03-08 1984-02-15 Kanebo Ltd Cosmetics containing 18-glycyrrhizins
LU86396A1 (fr) * 1986-04-18 1986-09-02 Pharma Roche Posay Lab Compositions pour le traitement de la calvitie et des alopecies
MX351117B (es) * 2011-02-25 2017-10-03 Desarrollos Vph S A De C V Formulacion de la sal acido glicirricinico en gel termorreversible y acido tricloroacetico para su aplicacion en el tracto genital de mujeres y varones con lesiones causadas por el virus del papiloma humano y cancer en los mismos.
RU2493852C1 (ru) * 2012-04-12 2013-09-27 Леонид Леонидович Клопотенко Композиция, содержащая фермент дезоксирибонуклеазу и/или стеарилглицирретинат или глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
CN105342987A (zh) * 2015-12-04 2016-02-24 亚飞（上海）生物医药科技有限公司 一种凝胶及其制备方法和应用
ITUB20159218A1 (it) * 2015-12-21 2017-06-21 Valitudo Pharma Srls Composizione, per uso topico, utile per favorire la cicatrizzazione di lesioni sulla pelle.
MX2017010806A (es) * 2017-08-22 2018-01-18 Atso Corp Affairs S A De C V Formulacion de acido 18-beta-glicirretinico en combinacion con revesterol y metformina, usos y metodo de fabricacion.

Also Published As

Publication number Publication date
EP4023219A1 (en) 2022-07-06
CA3147206A1 (en) 2021-02-11
WO2021025550A1 (es) 2021-02-11
CN114450001A (zh) 2022-05-06
MX2019009482A (es) 2021-02-09
US20220296544A1 (en) 2022-09-22
CO2022002493A2 (es) 2022-04-29
ZA202202125B (en) 2023-11-29
EP4023219A4 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
CN104922130B (zh) 一种用于治疗带状疱疹的凝胶剂及其制备方法
Leung et al. Herpes labialis: an update
Mazia et al. Formulation and evaluation of a mucoadhesive thermoresponsive system containing Brazilian green propolis for the treatment of lesions caused by herpes simplex type I
CL2022002084A1 (es) Formulaciones farmacéuticas
EA201890643A1 (ru) Лекарственные средства и медицинские изделия, содержащие ацетилсалициловую кислоту для лечения кожных инфекций, вызванных вирусом папилломы человека
BR112022002176A2 (pt) Nanoemulsão de ácido 18ss-glicirretínico.
ES2379474T3 (es) Producto dermatológico para el tratamiento y/o cuidado de la piel con neurodermitis
CO2022017324A2 (es) Composición farmacéutica acuosa de levilimab y su uso
CL2022003743A1 (es) Formulaciones de tableta dispersable que comprenden dolutegravir
Hebert et al. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps
BR112022010340A2 (pt) Composições farmacêuticas
Flora et al. Toxic epidermal necrolysis after yellow fever vaccination
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
Bunge et al. Phase I trial to assess safety, PK, and PD of film and gel formulations of tenofovir
BR112021025686A2 (pt) Formulação de doxorrubicina lipossomal, método para produzir uma formulação de doxorrubicina lipossomal e uso de uma formulação de doxorrubicina lipossomal como um medicamento
RU2488405C1 (ru) Лекарственное средство, обладающее противовирусным, противовоспалительным, иммуномодулирующим и обезболивающим действием, для местного и наружного применения - герпферон 2
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
Rakhmatulina et al. Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts
TR201619953A2 (tr) Topi̇kal terapöti̇k formülasyonlar
Pereira et al. Ozone therapy for herpes zoster: case report
WO2008110853A1 (es) Composición terapéutica tópica de origen vegetal para el tratamiento de la psoriasis y otras dermopatologias
ES2808864T3 (es) Método para tratar enfermedades recurrentes de la piel y la membrana mucosa provocadas por HSV-1 y HSV-2
Ambekar et al. COMPARISON OF ANTI-DIABETIC ACTIVITY OF GLIBENCLAMIDE LOADED ETHOSOMAL GELAND CONVENTIONAL GEL: IN-VIVO STUDY.